Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®

Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®

Tempus Communications
Erin Carron
media@tempus.com

Flatiron Health
Nina Toor
press@flatiron.com

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology, to integrate its comprehensive genomic testing directly into Flatiron’s cloud-based Electronic Medical Record (EMR) platform, OncoEMR® through the Molecular Profiling Integration (MPI). This integration will provide oncologists with seamless access to Tempus’ suite of testing options, enhancing their ability to deliver personalized cancer care.

Flatiron’s MPI—a two-way integration between laboratories and OncoEMR—will allow the 4,200 providers at more than 800 community-based cancer care locations across the U.S. in Flatiron’s network to order and receive results from Tempus directly in the OncoEMR workflow. The integration will enable electronic ordering, order tracking, and the receipt of Tempus test results directly within the OncoEMR platform, significantly reducing administrative burden and improving the experience for care providers.

“This collaboration represents a significant step forward in the integration of Tempus’ molecular profiling capabilities into everyday oncology practice,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “By leveraging Flatiron’s Molecular Profiling Integration within OncoEMR, we are enabling oncologists to access our comprehensive genomic tests with greater efficiency and precision, ultimately enhancing patient care and outcomes.”

“Integrating Tempus' suite of testing options into OncoEMR marks a step forward in personalizing cancer care, enabling more precise diagnoses and tailored treatments for every person with cancer,” said Stephen Speicher, MD, Senior Medical Director, Head of Clinical Oncology and Safety at Flatiron. “This collaboration ensures oncologists across the Flatiron network have convenient access to the information needed to practice precision medicine, improve patient outcomes, and spend more meaningful time with their patients, ultimately enhancing the care experience for both providers and those they serve.”

A key feature of this integration includes unified ordering in which a single order form will be deployed across all MPI-participating practices, streamlining the process and ensuring consistency. Also, this integration will give providers comprehensive access to Tempus tests, including xT, xR, xF/xF+, xG/xG+ Ambry, xM/xM (NeXT Personal® Dx), as well as several AI-enabled, algorithmic, add-on tests.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

About Flatiron Health

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding Tempus’ interoperability initiatives, integrations with electronic health record platforms, and efforts to reduce administrative burden associated with test ordering and results. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.